- Global Pharma News & Resources

Boehringer Ingelheim: Digital Lab BI X Facilitates Global Partnerships


  • Partnerships play an essential role for BI X in creating digitally innovative products and services to accelerate the development of better healthcare for humans and animals
  • Among other topics, BI X is searching for partners in the areas of complex neurological rehabilitation and single-cell multimodal omics technologies
  • Second hub in Shanghai and new partnership platform to provide more cooperation


Ingelheim, December 1, 2020 – BI X, the digital lab of Boehringer Ingelheim, is taking the next step in pursuing new partnerships in digital healthcare. The company targets a wide range of potential partners with its new partnership activities: This encompasses research groups, startups with concepts or prototypes for validation, and scale-ups, which have already existing digital products ready to expand to tech companies. Among others, the focus is currently on partnerships in the areas of complex neurological rehabilitation as well as single-cell multimodal omics technologies (scMulti-omics) in therapeutic research areas with a high unmet medical need. These therapeutic areas include cardiometabolic diseases, central nervous system diseases, respiratory diseases, immunology and oncology.


“Partnerships play a crucial role for Boehringer Ingelheim and BI X, to become faster in bringing valuable digital solutions to our patients and customers”, says Dr. Jasmin Saric, Head of Ideation and Scouting at BI X. “We consider co-creation, collaboration and speed as the key ingredients to addressing and managing the complexity of digital healthcare challenges.”


BI X is offering a variety of collaboration options, including scouting missions, accelerator programs, co-development, strategic partnerships, and client relationships. A new partnership platform will support BI X in the relationship management with new partners. It will enable BI X to provide even more comprehensive and targeted information to potential partners and simplify communication streams at the same time. 

In line with these developments, BI X has opened a second hub in Shanghai, China in the first half of 2020. “With our new office in Shanghai, we have significantly expanded our global presence and are now an attractive partner for the growing Chinese market”, explains Dr. Daniel Hach, Chief Operating Officer (COO) at BI X. “As part of one of the leading 20 pharmaceutical companies in the world, we can build on a large company network and resources. New partnerships will help us to further increase our global impact”.


Potential Partners can register at the partnership platform via:


BI X will be participating at the 2020 Web Summit (December 2-4), the world’s largest technology conference.


Boehringer Ingelheim

Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.


As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In 2019, Boehringer Ingelheim achieved net sales of 19 billion euros. Our significant investment of almost 3.5 billion euros in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.


We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.


More information about Boehringer Ingelheim can be found at or in our annual report:


Editor Details

  • Company:
    • Boehringer Ingelheim
  • Name:
    • Boehringer Ingelheim
Last Updated: 02-Dec-2020